Alaunos Therapeutics, Inc. (TCRT) Income Statement
TCRT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTCRT revenue and net income
Where TCRT's revenue goes
2025Each bar shows an amount and its share of revenue. TCRT kept −83,520.0% of revenue as net income.
TCRT profit margins
TCRT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −50.0% | −88.0% | — | −49.2% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TCRT quarterly EPS vs estimates
Alaunos Therapeutics beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 13, 2026.
TCRT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 | $0 | $0 | $146,000 | $6.4M | $6.9M |
| Cost of revenue | $1.4M | $362,000 | $4.8M | $22.5M | $47.3M | $1.1M | $629,000 | $0 | $0 | $0 |
| Gross profit | −$1.4M | −$352,000 | −$4.8M | −$19.6M | −$46.9M | −$1.1M | −$629,000 | $146,000 | $6.4M | $6.9M |
| Research & development | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M | $52.7M | $38.3M | $34.1M | $45.1M | $157.8M |
| Sales, general & admin | $2.9M | $4.5M | $12.2M | $13.1M | $26.3M | $27.7M | $19.5M | $19.9M | $14.8M | $14.4M |
| Total operating expenses | $2.9M | $4.5M | $29.5M | $15.5M | $30.7M | $80.4M | $57.2M | $54.1M | $59.9M | $172.2M |
| Operating income | −$4.2M | −$4.8M | −$34.3M | −$35.1M | −$77.5M | −$80.4M | −$57.9M | −$53.9M | −$53.5M | −$165.3M |
| Interest expense | — | $0 | $1.9M | $3.2M | $1.2M | $385,000 | $120.7M | $789,000 | $830,000 | $10,000 |
| Income before taxes | −$4.2M | −$4.7M | −$35.1M | −$37.7M | −$78.8M | −$80.0M | −$117.8M | −$53.1M | −$54.3M | −$165.3M |
| Income taxes | — | — | $2.1M | −$133,000 | −$1.9M | −$1.1M | $60.1M | −$947,000 | $2.1M | $114,000 |
| Net income | −$4.2M | −$4.7M | −$35.1M | −$37.7M | −$78.8M | −$78.8M | −$117.8M | −$53.1M | −$54.3M | −$165.3M |
| EBITDA | −$4.2M | −$4.7M | −$30.9M | −$31.8M | −$75.0M | −$79.2M | −$117.2M | −$53.3M | −$53.1M | −$165.0M |
| EPS (diluted) | −$2.14 | −$18.96 | −$16.90 | −$21.04 | −$48.05 | −$42.11 | −$90.09 | −$60.08 | −$61.63 | −$45.11 |
| Gross margin | −27,160.0% | −3,520.0% | −95,960.0% | −670.6% | −11,778.1% | — | — | 100.0% | 100.0% | 100.0% |
| Operating margin | −84,500.0% | −48,120.0% | −685,340.0% | −1,201.4% | −19,484.7% | — | — | −36,921.9% | −837.3% | −2,409.4% |
| Net margin | −83,520.0% | −46,790.0% | −702,800.0% | −1,291.2% | −19,786.7% | — | — | −36,381.5% | −850.3% | −2,409.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3,000 | $0 | $0 | $2,000 | $4,000 | $0 | $4,000 | $1,000 | $1,000 | $0 |
| Cost of revenue | $9,000 | $8,000 | $361,000 | $469,000 | $185,000 | $347,000 | $0 | $143,000 | $180,000 | $2,000 | — | $1.1M |
| Gross profit | −$9,000 | −$8,000 | −$358,000 | −$469,000 | −$185,000 | −$345,000 | $4,000 | −$143,000 | −$176,000 | −$1,000 | — | −$1.1M |
| Research & development | $388,000 | $427,000 | $361,000 | $469,000 | $185,000 | $347,000 | $86,000 | $143,000 | $180,000 | $126,000 | $933,000 | $3.7M |
| Sales, general & admin | $564,000 | $585,000 | $549,000 | $718,000 | $854,000 | $747,000 | $845,000 | $1.0M | $990,000 | $1.6M | $2.4M | $3.6M |
| Total operating expenses | $943,000 | $1.0M | $549,000 | $718,000 | $853,999 | $747,000 | $759,000 | $1.0M | $990,000 | $1.7M | $3.4M | $6.2M |
| Operating income | −$952,000 | −$1.0M | −$907,000 | −$1.2M | −$1.0M | −$1.1M | −$755,000 | −$1.1M | −$1.2M | −$1.7M | −$3.4M | −$7.2M |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $3.8M | $0 | $0 |
| Income before taxes | −$952,000 | −$1.0M | −$893,000 | −$1.2M | −$1.1M | −$1.1M | −$742,000 | −$1.1M | −$1.1M | −$1.7M | −$7.8M | −$8.5M |
| Income taxes | — | — | — | — | — | $41,276 | — | — | — | −$837,000 | — | $188,000 |
| Net income | −$952,000 | −$1.0M | −$893,000 | −$1.2M | −$1.1M | −$1.1M | −$742,000 | −$1.1M | −$1.1M | −$1.7M | −$7.8M | −$8.5M |
| EBITDA | −$943,000 | −$998,000 | −$886,000 | −$1.2M | −$1.1M | −$1.1M | −$742,000 | −$1.1M | −$1.1M | −$1.7M | — | −$7.4M |
| EPS (diluted) | −$0.41 | — | — | −$0.55 | −$0.63 | −$0.67 | −$0.46 | −$0.70 | −$0.71 | −$17.09 | −$0.49 | −$4.41 |
| Gross margin | — | — | −11,933.3% | — | — | −17,250.0% | 100.0% | — | −4,400.0% | −100.0% | — | — |
| Operating margin | — | — | −30,233.3% | — | — | −54,600.0% | −18,875.0% | — | −29,150.0% | −174,200.0% | −336,000.0% | — |
| Net margin | — | — | −29,766.7% | — | — | −53,650.0% | −18,550.0% | — | −28,225.0% | −168,200.0% | −784,300.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TCRT's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TCRT financial results
In fiscal year 2025 (ended December 31, 2025), Alaunos Therapeutics reported revenue of $0.0 million, down 50.0% from the year before. It had a net loss of $4.2 million, a net profit margin of −83,520.0%. Diluted earnings per share came to −$2.14.
See the TCRT stock overview for the latest quote and news, or the TCRT chart for price history and technical indicators.
TCRT income statement FAQ
What is Alaunos Therapeutics's annual revenue?
Alaunos Therapeutics reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 50.0% from $0.0 million the previous year.
Is Alaunos Therapeutics profitable?
No. Alaunos Therapeutics reported a net loss of $4.2 million in fiscal 2025, a net profit margin of −83,520.0%; its operating margin was −84,500.0%.
What is Alaunos Therapeutics's gross margin?
Alaunos Therapeutics's gross margin was −27,160.0% in fiscal 2025: for every $100 of revenue, Alaunos Therapeutics kept $-27160 after the direct cost of its products and services.
How much does Alaunos Therapeutics spend on research and development?
Alaunos Therapeutics spent $1.4 million on research and development in fiscal 2025, 27,260.0% of revenue.
What are Alaunos Therapeutics's earnings per share?
Alaunos Therapeutics earned $-2.14 per diluted share in fiscal 2025, compared with $-18.96 a year earlier.
When will Alaunos Therapeutics report its next earnings?
Alaunos Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Alaunos Therapeutics's fiscal year end?
Alaunos Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.